In early October, we told our readers that Access Pharmaceuticals' (OTC: ACCP) stock had been acting very bullishly. Today's news looks to add fuel to their climb.

Just last week, ACCP submitted additional patent applications, covering that oral drug delivery technology formulations for many of the world's top-100 injectable drugs- all as a result of the growing interest surrounding the company’s proprietary oral delivery technology. 

Flash Player 9 or higher is required to view the chart Click here to download Flash Player now

Jeffrey B. Davis, President and CEO, Access Pharmaceuticals had hinted that “the CobOral branding and additional patent filings reflect the high level of interest from partners in our CobOral and CobaCyte drug delivery platforms.”

According to a press-release issued by the company, Access will develop CobOral formulations for testing by the undisclosed biopharma company. Access indicated that any successful formulation developed will be jointly owned by the Parties and subject to a subsequent full licensing agreement.

Developing...

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

---

Add this page to your favorite Social Bookmarking websites